CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 374 enrolled
Drug / intervention
IC51biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00595790
NCT00595790Phase 3Completed
CompareCT.gov

Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis

Valneva Austria GmbH·interventional·Posted Jan 16, 2008·Updated Apr 29, 2014

In Brief

A Phase 3 clinical trial evaluating IC51 for Japanese Encephalitis. Completed, enrolled 374 participants.

Detailed Summary

The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged \> or = 18 years

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2008
Enrollment StartSep 1, 2005
Primary CompletionFeb 1, 2006
Study CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.5 years ago

Interventions

IC51biological